Sol-Gel Technologies Ltd. - Ordinary Shares (NQ:SLGL)

69.45 +2.06 (+3.06%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sol-Gel Technologies Ltd. - Ordinary Shares

< Previous 1 2 Next >

Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data ↗

October 14, 2026

Sol-Gel Technologies (NASDAQ:SLGL) outlined its development and commercialization plans for SGT-610, a topical patidegib treatment being studied to reduce new basal cell carcinomas (BCCs) in patients...

Via MarketBeat

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 07, 2025

Via Benzinga

Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 22, 2025

Via Benzinga

Sol-Gel Technologies: Q4 Earnings Insights ↗

March 13, 2024

Via Benzinga

Recap: Sol-Gel Technologies Q3 Earnings ↗

November 09, 2023

Via Benzinga

Expert Ratings for Sol-Gel Technologies ↗

August 11, 2023

Via Benzinga

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic ↗

May 23, 2025

The company’s diluted loss per share came in at $3.2, exceeding an estimated loss of $1.2.

Via Stocktwits

Topics Government

US Stocks Gain, Nasdaq Surges Over 100 Points ↗

December 24, 2024

Via Benzinga

Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket ↗

December 24, 2024

Via Benzinga

SLGL Stock Earnings: Sol-Gel Technologies Beats EPS, Beats Revenue for Q2 2024 ↗

August 16, 2024

SLGL stock results show that Sol-Gel Technologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024 ↗

May 20, 2024

SLGL stock results show that Sol-Gel Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Sol-Gel Technologies: Q1 Earnings Insights ↗

May 13, 2022

Sol-Gel Technologies (NASDAQ:SLGL) reported its Q1 earnings results on Friday, May 13, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 25, 2024

Via Benzinga

Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal ↗

May 19, 2024

In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones.

Via Talk Markets

Stocks That Hit 52-Week Lows On Thursday ↗

October 05, 2023

On Thursday, 369 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 29, 2023

Friday's session saw 112 companies set new 52-week lows.

Via Benzinga

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) Making Surprising Moves in Wednesday Session

March 22, 2023

Via Investor Brand Network

7 Biotech Stocks That Could Be the Next Big Thing ↗

March 15, 2023

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Tuesday ↗

September 26, 2023

On Tuesday, 386 stocks made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 15, 2023

Friday's session saw 169 companies set new 52-week lows.

Via Benzinga

The Top 7 Penny Stocks to Invest in for the Long-Term ↗

February 23, 2023

Although penny stocks represent extremely high risks, a select few ideas could make for enticing long-term propositions.

Via InvestorPlace

Heska To $165? Plus BTIG Cuts PT On This Stock By 67% ↗

November 14, 2022

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at...

Via Benzinga

Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 22, 2023

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.

Via Benzinga

What Does Sunshine Biopharma's Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market? ↗

November 07, 2022

The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them.

Via Benzinga

Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge ↗

October 24, 2022

U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022 ↗

October 21, 2022

Upgrades

Via Benzinga

Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session ↗

June 29, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday ↗

July 18, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering...

Via Benzinga

Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session ↗

July 15, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday.

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.